Please login to the form below

Not currently logged in
Email:
Password:

pharma merger

This page shows the latest pharma merger news and features for those working in and with pharma, biotech and healthcare.

Pfizer could raise ‘up to $15bn’ from consumer unit sale

Pfizer could raise ‘up to $15bn’ from consumer unit sale

of failed merger attempts with AstraZeneca and Allergan, the takeovers of Hospira and cancer specialist Medivation, and the divestment of Hospira’s infusions unit. ... been persistent speculation that it is still looking to complete a mega-merger with

Latest news

  • Xtandi slowdown weighs on Pfizer, but CEO won't move on M&A Xtandi slowdown weighs on Pfizer, but CEO won't move on M&A

    Investors call on the pharma giant to consider a large merger or acquisition deal. ... Pfizer walked away from a $160bn merger with Allergan last year, blaming a clampdown on so-called tax inversion deals.

  • US tax changes claim Pfizer scalp as Allergan deal abandoned US tax changes claim Pfizer scalp as Allergan deal abandoned

    The mega-merger would have created the world's largest pharma company, valued at around $330bn, but relied on the US firm benefiting from Ireland's lower corporate tax rate. ... While in a statement the White House said the new rules were not calculated

  • Baxalta agrees to $32bn Shire takeover Baxalta agrees to $32bn Shire takeover

    Shire said the post-merger firm will be able to deliver double-digit sales growth to more than $20bn by 2020, with around two-thirds of its turnover coming from rare ... Pharma companies are increasingly drawn to rare diseases as they can generally

  • Actelion claims first approval for PAH therapy Uptravi Actelion claims first approval for PAH therapy Uptravi

    It was also in discussions about a merger with ZS Pharma, before the latter opted instead for a $2.7bn takeover by AstraZeneca (AZ).

  • Reckitt to spin-off pharma unit as Indivior Reckitt to spin-off pharma unit as Indivior

    Reckitt to spin-off pharma unit as Indivior. Demerged business will focus on opioid dependence product Suboxone. ... The company's pharma sales shrank 8% in the first half of this year to £344m, while the remainder of the group saw net revenues decline 7

More from news
Approximately 2 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    For an indepth analysis of these deals, read'Pharma deals during March 2014'. ... Vidara Therapeutics/. Horizon Pharma. Merger/ acquisition. Actimmune (interferon gamma-1b) for CGD and SMO (approved).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Reig Jofre boosts Forté Pharma’s senior team Reig Jofre boosts Forté Pharma’s senior team

    Reig Jofre boosts Forté Pharma’ s senior team. Appoints Alain Boutboul as the nutritional supplements group’s general manager. ... Ignasi Biosca, chief executive officer, Reig Jofre, said: “We had been working for some time on Forté Pharma's

  • Vifor Pharma appoints Dario Eklund Vifor Pharma appoints Dario Eklund

    Vifor Pharma has named Dario Eklund as their head of international business operations. ... Prior to that, he was general manager of Switzerland for Aventis Pharma, until its 2004 merger with Sanofi, and earlier in his career he held a number of

  • Merck & Co appoints new financial head Merck & Co appoints new financial head

    Kellogg had been in the position since joining Merck in 2007 and played a key role in the pharma company's merger with Schering-Plough.

  • Cipher names Gerald McDole as chair Cipher names Gerald McDole as chair

    Cipher has appointed pharma veteran Gerald McDole as chair of the board of directors. ... Prior to this he was president and CEO of Astra Pharma in Canada before its merger with Zeneca.

  • Merck Serono appoints chief medical officer Merck Serono appoints chief medical officer

    Dr Steven Hildemann has left the US-based Merck &Co to join its German namesake Merck KGaA as chief medical officer of its pharma business Merck Serono. ... He joined Merck &Co after the US pharma giant merger with his former company, Schering-Plough, in

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics